Published in Cancer Weekly, May 3rd, 2005
The company plans to initiate a dose-ranging phase 1 trial of ZIO-101 in patients with hematological cancers. The trial will be conducted at the University of Texas M.D. Anderson Cancer Center in Houston, Texas.
Ziopharm is a privately held company and was founded in January 2004 to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer therapies.
The company's first in-licensed product in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.